Literature DB >> 19578107

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort.

L A González1, G J Pons-Estel, J Zhang, L M Vilá, J D Reveille, Graciela S Alarcón.   

Abstract

The aims of this study were to examine the predictors of time to neuropsychiatric (NP) damage and its impact on mortality in 632 systemic lupus erythematosus African-American, Hispanic and Caucasian LUpus in MInorities: NAture versus Nurture (LUMINA) patients, age >or= 16 years and disease duration <or=5 years at baseline (T0). Time-to-NP damage and its impact on mortality were examined by Cox proportional hazards regressions. A total of 185 (29.3%) patients developed NP damage over a mean (SD) disease duration of 5.6 (3.7) years. After adjusting for NP manifestations present, older age [Hazard ratio (HR) = 1.02; 95% Confidence interval (CI) 1.00-1.04], Caucasian ethnicity (HR = 1.87; 95% CI, 1.22-2.87), disease activity over the disease course (HR = 1.16; 95% CI, 1.12-1.21), diabetes (HR = 3.47; 95% CI, 1.44-8.38) and abnormal illness-related behaviours (HR = 1.05; 95% CI, 1.02-1.08) were associated with a shorter time-to-NP damage. Photosensitivity (HR = 0.65; 95% CI, 0.44-0.95), anaemia (HR = 0.56; 95% CI, 0.31-0.98), Raynaud's phenomenon (HR = 0.49; 95% CI, 0.34-0.72), a medium dose of prednisone (HR = 0.56; 95% CI, 0.35-0.92) and hydroxychloroquine use (HR = 0.58; 95% CI, 0.36-0.93) were associated with a longer time. NP damage did not contribute to mortality. Older age, Caucasian ethnicity, disease activity and abnormal illness-related behaviours are associated with a shorter time-to-NP damage; hydroxychloroquine and a medium dose of prednisone with a longer time.

Entities:  

Mesh:

Year:  2009        PMID: 19578107      PMCID: PMC3759150          DOI: 10.1177/0961203309104392

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  39 in total

1.  Hopkins Lupus Cohort. 1999 update.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2000-05       Impact factor: 2.670

Review 2.  The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.

Authors:  Robert B M Landewé
Journal:  Arthritis Rheum       Date:  2003-01

3.  The impact of the 1997 update of the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: what has been changed?

Authors:  Marie Feletar; Dominique Ibañez; Murray B Urowitz; Dafna D Gladman
Journal:  Arthritis Rheum       Date:  2003-07

4.  Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.

Authors:  G S Alarcón; G McGwin; H M Bastian; J Roseman; J Lisse; B J Fessler; A W Friedman; J D Reveille
Journal:  Arthritis Rheum       Date:  2001-04

5.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

6.  Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis.

Authors:  H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille
Journal:  Lupus       Date:  2002       Impact factor: 2.911

7.  Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality.

Authors:  A Jönsen; A A Bengtsson; O Nived; B Ryberg; G Sturfelt
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

8.  Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual.

Authors:  G S Alarcón; G McGwin; A A Bartolucci; J Roseman; J Lisse; B J Fessler; H M Bastian; A W Friedman; J D Reveille
Journal:  Arthritis Rheum       Date:  2001-12

9.  High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life.

Authors:  Irene E M Bultink; Franktien Turkstra; Ben A C Dijkmans; Alexandre E Voskuyl
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

10.  Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.

Authors:  Estelle Trysberg; Karin Nylen; Lars E Rosengren; Andrej Tarkowski
Journal:  Arthritis Rheum       Date:  2003-10
View more
  11 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

3.  Hydroxychloroquine-Induced Erythema Multiforme.

Authors:  Nour Abou Assalie; Robert Durcan; Laura Durcan; Michelle A Petri
Journal:  J Clin Rheumatol       Date:  2017-03       Impact factor: 3.517

4.  Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Renato Goreshi; Rachel Klein; Joyce Okawa; Mathew Rose; Andrew Cucchiara; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

5.  The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).

Authors:  Yufang Ding; Jiuliang Zhao; Junyan Qian; Li Zhang; Shangzhu Zhang; Nan Jiang; Jing Li; Chanyuan Wu; Qingjun Wu; Dong Xu; Xiaomei Leng; Qian Wang; Wen Zhang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2022-01-27       Impact factor: 2.980

Review 6.  To what extent can preventive treatments prevent damage from systemic lupus erythematosus?

Authors:  Elena M Massarotti; Peter H Schur
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.686

Review 7.  Neuropsychiatric lupus: a mosaic of clinical presentations.

Authors:  Shaye Kivity; Nancy Agmon-Levin; Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2015-03-04       Impact factor: 8.775

Review 8.  Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients?

Authors:  Raquel Faria; João Gonçalves; Rita Dias
Journal:  Rambam Maimonides Med J       Date:  2017-01-30

9.  Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations.

Authors:  Shuang Liu; Yuqi Cheng; Yueyin Zhao; Aiyun Lai; Zhaoping Lv; Zhongqi Xie; Bibhuti Upreti; Xiangyu Wang; Xiufeng Xu; Chunrong Luo; Hongjun Yu; Baoci Shan; Lin Xu; Jian Xu
Journal:  J Immunol Res       Date:  2020-06-12       Impact factor: 4.818

Review 10.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.